Pfizer terminates license to three products with Acura Pharmaceuticals

The three products all used Acura's AVERSION Technology, and they will return to Acura, said termination becoming effective in 12 months under the terms of Acura’s license agreement with a subsidiary of Pfizer
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
PALATINE, Ill.—Acura Pharmaceuticals Inc., aspecialty pharmaceutical company developing products intended to addressmedication abuse and misuse, announced July 30 that Pfizer Inc. had a few daysearlier provided notice that it is exercising its right to terminate thelicense to three development-stage products.
 
 
The three products all used Acura's AVERSIONTechnology, and they will return to Acura, said termination becoming effectivein 12 months under the terms of Acura's license agreement with a subsidiary ofPfizer.
 
 
The products being returned are oxycodone hydrochloridewith acetaminophen, hydrocodone bitartrate with acetaminophen and anundisclosed opioid. The hydrocodone product is the most advanced indevelopment, with a clinical study completed in February 2012 that reportedly demonstratedbioequivalence to its reference-listed drug. This product also was the subjectof a pre-IND meeting held with the U.S. Food and Drug Administration (FDA) inMay 2012 in which the FDA agreed to a development program for this productgenerally consistent with that used for another drug using the AVERSIONtechnology, known as OXECTA (oxycodone hydrochloride) Tablets CII.
 
 
"We are pleased to regain control of thesetamper-resistant opioid products because we continue to believe they holdpromise in combating widespread prescription opioid abuse," said BobJones, president and CEO of Acura Pharmaceuticals. "We will evaluate ourstrategy for these products over the coming months, including possiblepartnering with alternative strategic partners, and will work with Pfizer toexercise our rights under the Pfizer agreement for the transition of these productsback to us."
 
 
As for OXECTA, that drug is being commercializedby Pfizer and Pfizer will retain all rights and obligations to OXECTA under thelicense agreement.
 
 
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Characterizing lipid nanoparticles for RNA therapeutic development
Integrated multiomics and advanced nanoparticle analytics are improving how researchers perform RNA delivery, increasing therapeutic success.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue